Purpose:　To　determine　the　effects　of　intraoperative　dexmedetomidine　(DEX)　administration　on　postoperative　ischaemia/reperfusion　injury　(HIRI)　and　clinical　outcomes　of　patients　undergoing　the　laparoscopic　living　donor　hepatectomy　(LLDH).　Patients　and　Methods:　Fifty-five　patients　who　underwent　the　LLDH　were　randomly　assigned　to　the　DEX　or　control　group.　The　DEX　group　received　an　intravenous　infusion　of　DEX　with　an　bolus　dose　of　1　mu　g/kg　for　15　min　before　anaesthesia　induction,　followed　by　a　continuous　infusion　at　a　rate　of　0.4　mu　g/kg/h　until　the　portal　branch　was　disconnected.　The　control　group　was　given　an　intravenous　infusion　of　0.9%　saline　at　same　volume　and　rate.　The　primary　outcome　was　peak　serum　aspartate　aminotransferase　(AST)　level　during　the　first　72　h　postoperatively.　The　secondary　outcomes　included　other　variables　of　postoperative　liver　and　kidney　function,　intraoperative　hemodynamic　changes,　postoperative　recovery　outcomes　and　the　occurrence　of　complications.　Results:　The　peak　serum　AST　level　during　the　first　72　h　postoperatively　was　not　significantly　different　between　groups　(DEX　vs　control:　288　[194-466]　vs　324　[194-437]　IU/L;　difference,　-1.2　IU/L;　95%　CI,　-86.9　to　88.0;　P=0.973).　The　intraoperative　mean　artery　pressure　was　not　significantly　different,　but　intraoperative　heart　rate　was　significantly　decreased　in　the　DEX　group.　There　were　no　significant　differences　between　groups　in　other　secondary　outcomes.　Conclusion:　This　study　demonstrates　that　intraoperative　DEX　administration　at　the　studied　dosage　regimens　cannot　attenuate　postoperative　HIRI　and　does　not　improve　clinical　outcomes　in　patients　undergoing　the　LLDH.